Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Palo Alto Medical Foundation-Gynecologic Oncology
mi
from
Mountain View, CA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Palo Alto Medical Foundation-Gynecologic Oncology
mi
from
Mountain View, CA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
The Hartford Hospital
mi
from
Hartford, CT
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
The Hospital of Central Connecticut
mi
from
New Britain, CT
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Rush University Medical Center
mi
from
Chicago, IL
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Mercy Medical Center-West Lakes
mi
from
West Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Mercy Medical Center-West Lakes
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Associates in Women's Health
mi
from
Wichita, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Associates in Women's Health
mi
from
Wichita, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas - Main Office
mi
from
Wichita, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas - Main Office
mi
from
Wichita, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Via Christi Regional Medical Center
mi
from
Wichita, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Wichita NCI Community Oncology Research Program
mi
from
Wichita, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Wichita NCI Community Oncology Research Program
mi
from
Wichita, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Mercy Hospital Springfield
mi
from
Springfield, MO
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cox Medical Center South
mi
from
Springfield, MO
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Nebraska Methodist Hospital
mi
from
Omaha, NE
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Saint Luke's Hospital-Warren Campus
mi
from
Phillipsburg, NJ
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Saint Luke's Hospital-Warren Campus
mi
from
Phillipsburg, NJ
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Cincinnati
mi
from
Cincinnati, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Riverside Methodist Hospital
mi
from
Columbus, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Kettering Medical Center
mi
from
Kettering, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Abington Memorial Hospital
mi
from
Abington, PA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Women and Infants Hospital
mi
from
Providence, RI
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
PeaceHealth Medical Group PC
mi
from
Bellingham, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
PeaceHealth Medical Group PC
mi
from
Bellingham, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison Medical Center
mi
from
Bremerton, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison Medical Center
mi
from
Bremerton, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Providence Regional Cancer Partnership
mi
from
Everett, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Skagit Valley Hospital Regional Cancer Care Center
mi
from
Mount Vernon, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Skagit Valley Hospital Regional Cancer Care Center
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Pacific Gynecology Specialists
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials